Clinical Scorecard: Immune and Cellular Factors Shaping Response to Hypomethylating Agent–Venetoclax Therapy in Acute Myeloid Leukemia
At a Glance
Category
Detail
Condition
Acute myeloid leukemia treated with hypomethylating agent–venetoclax therapy
Key Mechanisms
The article examines leukemia-intrinsic resistance mechanisms and immune and tumor-microenvironment features associated with response; previously described mechanisms include increased MCL1 expression, BAX mutations, and TP53, NRAS, or FLT3 alterations.
Target Population
Adults with AML receiving HMA–venetoclax; the retrospective cohort included 132 patients, and single-cell profiling was performed in 10 patients with newly diagnosed de novo AML.
Care Setting
Retrospective clinical cohort and bone-marrow single-cell research; the article describes frontline and later-line HMA–venetoclax treatment.
Key Highlights
The retrospective cohort included 132 patients with AML treated with HMA–venetoclax; 65 received it as first-line therapy and 67 in later treatment lines.
Molecular profiling was available for 99 of 132 patients; the most frequent reported mutations were TET2 (29%), DNMT3A (27%), NPM1 (22%), and ASXL1 (20%).
Single-cell RNA sequencing was performed in 10 patients with newly diagnosed de novo AML, using bone-marrow samples at diagnosis and after cycle one.
Response categories for the single-cell subset were CR/CRi, early relapse after an initial response, and refractory disease at the post-cycle-one sampling timepoint.
The study was designed to investigate molecular and immunological determinants of HMA–venetoclax response; the supplied article excerpt does not include the subsequent results.
Guideline-Based Recommendations
Diagnosis
The study assessed AML response using European Leukemia Network response criteria.
For the single-cell subset, refractory disease was defined as persistent active disease at the post-cycle-one sampling timepoint; early relapse was an initial response followed by treatment failure within the first four treatment cycles.
Management
The article describes HMA combined with venetoclax as a treatment approach used in older or unfit patients and in both frontline and later-line settings.
The supplied excerpt does not provide treatment recommendations or regimen details.
Monitoring & Follow-up
In the single-cell subset, bone-marrow aspirates were collected at diagnosis and after cycle one (median day 27; range 24–51).
The excerpt reports a median follow-up of 17.06 months for the overall cohort at the survival-analysis update.
Risks
The introduction states that remissions after HMA–venetoclax are frequently brief and relapse commonly occurs.
The article describes resistance mechanisms reported in prior studies, including increased expression of alternative anti-apoptotic proteins such as MCL1, BAX mutations, and alterations involving TP53, NRAS, and FLT3.
The introduction reports associations between persistent IFN-γ signaling, particularly in TP53-mutated AML, and immune exhaustion, resistance to genotoxic stress, and adverse outcomes.
Patient & Prescribing Data
The retrospective cohort comprised 132 patients with AML, including newly diagnosed and relapsed/refractory disease. Ten consecutive patients with newly diagnosed de novo AML underwent single-cell RNA sequencing.
Patients received HMA–venetoclax as first-line therapy (65 patients) or in later treatment lines (67 patients). The supplied excerpt does not specify drug doses, schedules, or prescribing adjustments.
Clinical Best Practices
Interpret the single-cell findings in the context of the study subset: 10 patients with newly diagnosed de novo AML.
Distinguish early relapse from refractory disease using the study definitions and sampling timepoint.
Note that molecular profiling was performed in 99 of 132 patients, rather than the full cohort.
